PMID: 7036334Dec 12, 1981Paper

Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study

Schweizerische medizinische Wochenschrift
F Rhomberg, J Widler

Abstract

Alpha-methyldopa and guanfacine, both of which are predominantly centrally acting antihypertensives, were compared in a double-blind randomized trial involving seven practising physicians and a total of 78 patients. The whole trial lasted one year, with individual treatment periods of between 5 and 14 weeks. The reduction achieved in mean systolic and also diastolic blood pressure did not differ significantly between the two groups; nor was there any significant difference in responder or nonresponder rates. Blood pressure was normalized in approximately 80% of the patients in both groups. The incidence of side effects was kept down by starting treatment with a low dose and increasing it gradually. The average dose at the end of the trial was 2.6 mg daily for the guanfacine patients and 750 mg daily for those given alphamethyldopa.

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.